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Abstract Catestatin, an endogenous peptide derived from
bovine chromogranin A, and its active domain cateslytin
display powerful antimicrobial activities. We have tested
the activities of catestatin and other related peptides on the
growth of Plasmodium falciparum in vitro. Catestatin
inhibits growth of the chloroquine-sensitive strain of
P. falciparum 3D7, exhibiting 88% inhibition at 20 lM.
A similar partial inhibition of parasite growth was observed
for the chloroquine-resistant strain, 7G8 (64%,) and the
multidrug-resistant strain, W2 (62%). In the presence of
parasite-specific lactate dehydrogenase, a specific protein–
protein interaction between catestatin and plasmepsin II
precursor was demonstrated. In addition, catestatin par-
tially inhibited the parasite-specific proteases plasmepsin in
vitro. A specific interaction between catestatin and
plasmepsins II and IV from P. falciparum and plasmepsin
IV from the three remaining species of Plasmodium known
to infect man was observed, suggesting a catestatin-
induced reduction in availability of nutrients for protein
synthesis in the parasite.
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Introduction
A series of antimicrobial peptides were derived from the
processing of the adrenomedullary chromogranins A and B
(CgA and CgB), proenkephalin-A, and ubiquitin, all
co-stored and co-secreted with catecholamines upon stim-
ulation of the chromaffin cells [1–7]. Eight pairs of dibasic
residues in bovine CgA correspond to major sites for
processing in the intragranular matrix [8] to generate sev-
eral bioactive peptides [9], among them a 21-residue-long
cationic peptide (net charge ?5) named catestatin (bovine
CgA344–364, bCts). This peptide was initially character-
ized for its inhibitory effect on catecholamine secretion
from chromaffin cells of the adrenal medulla [10, 11], and
was identified as a product from stimulated chromaffin
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cells [12]. The sequence of Cts is highly conserved in
mammals (Table 1) [13–19], and cateslytin (bovine
CgA344–358, CTL) corresponds to the antimicrobial
active domain [2]. The antibacterial potency of the CTL
domain has been confirmed in studies of Cts as an anti-
bacterial agent in human skin [20]. A role for these
antimicrobial CgA peptides in innate immunity was dem-
onstrated by their presence in secretions of stimulated
polymorphonuclear neutrophils (PMNs) [2] and by the fact
that Cts activates neutrophils by inducing calcium entry
[21].
Malaria is endemic in about 100 developing countries
and over 3 billion people live under the threat of malaria
infection. Malaria causes over 1 million deaths each year,
most of whom are children [22, 23]. The most recent
estimates indicate that there are more than 500 million
clinical cases of malaria annually on the planet, a number
that nearly doubles previous estimates [24, 25], and the
disability adjusted life years (DALYs) of malaria are esti-
mated at 45 million [23]. Furthermore, drug resistance of
P. falciparum has emerged in all classes of antimalarial
drugs [26, 27], and increased efforts in antimalarial drug
discovery are urgently needed [28, 29]. Because some
antiplasmodial agents are host cytotoxic molecules [30],
natural non-toxic peptides might represent a new approach
for malaria drug research.
Plasmepsins are aspartic proteases involved in the deg-
radation of the host cell haemoglobin, providing nutrients
for parasite growth [31] and other as yet unidentified
functions. Novel and potent inhibitors of Plasmodium
plasmepsins were identified by using an automated proce-
dure to post-process the results of a large docking screen of
commercially available compounds. Efforts to design new
inhibitors against malarial plasmepsins have employed a
range of computational tools in the design process,
including homology modeling, automated docking, enzyme
reaction simulations, and microscopic calculations of
binding free energies [32]. Malaria parasites, both in cul-
ture and in animal models, are killed by inhibitors of
plasmepsins, establishing proof of concept that these pro-
teases are important as drug targets [33], especially when
combined with the inhibition of falcipains that are also
involved in haemoglobin degradation [32]. Previous stud-
ies have indicated that several peptidomimetics inhibitors,
obtained from combinatorial chemistry based peptides
libraries, have a high inhibitory effect on various plasm-
epsins [34]. Because some of these inhibitors show
sequence similarities with Cts, we investigated the effect of
Cts on Plasmodium growth.
The aim of the present study was to probe Cts and CTL
for their antimalarial activities. Our results show that Cts
inhibits growth of several strains of P. falciparum, not only
the chloroquine-sensitive strain 3D7 but also the chloro-
quine-resistant (7G8) and the multidrug-resistant (W2)
strains. The structural parameters crucial for the antima-
larial potency have been identified, as well as a potential
plasmodial target protein within the plasmepsin family [35].
Materials and methods
Synthetic peptides
The synthetic peptides were prepared with an Applied
Biosystems 433 A synthesizer (Foster City, USA), using
the stepwise solid-phase method with 9-fluoromethoxy-
carbonyl (Fmoc chemistry) [2, 36]. As a negative control,
we used the inactive scrambled Cts breaking the putative
secondary structure (SLPRRQLPSSAGMRGGKFAYF).
For fluorescence studies, rhodaminated peptides were
obtained as previously reported [6]. Synthetic peptides
were finally purified by HPLC on C18 reverse-phase
Table 1 Alignment of Cts from
different species and sequence
similarity (%)
Homolog residues are in white
letter by comparison with
human Cts
h human, b bovine, m mouse,
r rat, e equine, p pig, f frog,
– deletion
Sequence
Similarity
(%)
Ref.
hCGA352-372 S S M K L S F R A R A Y G F R G P G P Q L 100 [13] 
bCGA344-364 R S M R L S F R A R G Y G F R G P G L Q L 90 [14] 
mCGA364-384 R S M K L S F R T R A Y G F R D P G P Q L 86 [15] 
rCGA367-387 R S M K L S F R A R A Y G F R D P G P Q L 95 [16] 
eCGA361-381 R S M K L S F R A R A Y G F R G P G L Q L 90 [17] 
pCGA343-363 R S M K L S F R A P A Y G F R G P G L Q L 86 [18] 
fCGA318-335 R S M K I P T K D Q K Y - - - E P A S E E 38 [19] 
Consensus
sequence
R S M K
R
L
I
S F R
K
A R A
G
Y G F R P G
A
Q L  [13] 
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columns and lyophylized. Purity of the synthetic peptides
([98%) was established by HPLC and MALDI-TOF mass
spectrometry, and the concentration was evaluated by
automatic Edman sequencing [2] after correction with the
Edman degradation yield.
Study of peptide activity on P. falciparum strains
in vitro
We have used three P. falciparum strains with different
origin and chemo-sensitivities: an African strain sensitive
to chloroquine (3D7), a Brazilian strain resistant to chlo-
roquine (7G8), and a South-East Asian strain resistant to
chloroquine, quinine, and halofantrine (W2), kindly pro-
vided by Prof. S. Picot (EA 3732 Parasitologie, Mycologie
Me´dicale et Pathologie Exotique, Faculte´ de Me´decine,
Universite´ Claude Bernard, Lyon, France) and Prof. J. Le
Bras (EA 209 Centre National de Re´fe´rence pour la Chi-
miosensibilite´ du Paludisme, APHP, Hoˆpital Bichat-Claude
Bernard, Paris, France). The parasite strains were kept in
continuous culture with O? erythrocytes (Etablissement
Franc¸ais du Sang, Strasbourg, France) in a malaria culture
medium (MCM, pH 7.4) consisting of RPMI 1640 sup-
plemented with 2 mM L-glutamine, 10 mM Hepes (Gibco,
Invitrogen, Cergy Pontoise, France), 1 lg/ml hypoxan-
thine, 0.11 mg/ml Na pyruvate, and 0.02 mg/ml
gentamycin in the presence of 10% (v/v) alpha calf serum
(Perbio Science, Brebie`res, France) for the 3D7 strain or
10% (v/v) human group A?B? serum (Etablissement
Franc¸ais du Sang, Strasbourg, France) for the 7G8 or W2
strain, using an adapted candle jar method as previously
described [37–39]. The cultures were evaluated at 1%
haematocrit and 1% parasitemia. Ring-form stages and
schizonts of P. falciparum [40] were also examined. Stock
solution of aqueous peptides (1 mM) were prepared and
diluted to give final concentrations of 0.02–20 lM in
MCM. Antiparasitic activity was assessed at 24, 48, 72,
and 96 h of incubation. Scrambled Cts were used as neg-
ative controls. In preliminary experiments, scrambled Cts
was found to be inactive against the chloroquine-sensitive
strain 3D7 (data not shown).
Estimation of peptide effects on the parasite
infection rate
In order to estimate peptide effects on Plasmodium infec-
tion rate, the Plasmodium cultures were enriched with aged
forms (late trophozoites and schizonts) using Plasmion
(Laboratoires Fresenius Kabi, France), as previously
described [40]. Thereafter, young forms of Plasmodium
(ring stages) were counted after 24 h of incubation in the
presence of 50 lM Cts at 37C. Control experiments were
performed with scrambled Cts at the same conditions. In all
experiments, parasitemia was determined by light micro-
scope (9100), counting the proportion of parasitized red
blood cells (RBCs) in about 20 fields of thin blood films
prepared from culture. Mean and standard deviation were
calculated from three different experiments, each being
evaluated by three different readers [28]. In parallel,
Plasmodium-derived lactate dehydrogenase (pLDH), a
parasite-specific intracellular metabolic enzyme, was
measured in whole blood in the absence or presence of
peptides, using a commercial ELISA kit (DiaMed ELISA
Malaria Antigen test; Cressier sur Morat, Switzerland)
according to the manufacturer’s recommendations [41].
Each peptide was incubated in MCM at 20 lM for 48 h
before analysis by pLDH-ELISA. The pLDH test was used
to determine the 50% inhibitory concentration (IC50). The
IC50 was estimated by linear regression analysis (standard
curve) [ICEstimator software (http://www.antimalarial-
icestimator.net/)]. For each peptide or drug, the data from
the ELISA assay correspond to ten different concentra-
tions. For each concentration, the mean of triplicate
measurements was obtained and expressed in percent of the
enzyme activity obtained with the controls (100%).
Analysis of Cts stability in the culture medium
by reverse phase HPLC
Cts was incubated in MCM at 20 lM for 30 min to 24 h
before analysis by RP-HPLC. The MCM medium and an
aqueous solution of 20 lM Cts were used as separate
controls. The analyses were performed on a Macherey–
Nagel Nucleosil 300-5C18 column (4 9 250 mm) (Hoerdt,
France) with the Akta Purifier HPLC system (Amersham
Biosciences, Les Ulis, France). The solvent system con-
sisted of 0.1% (v/v) trifluoroacetic acid in water (solvent A)
and 0.09% (v/v) trifluoroacetic acid in 70% acetonitrile
(Carlo Erba, Rodano, Italy) in water (solvent B). Elutions
were performed at a flow rate of 700 lL/min using the
gradient % B (0–10) for the first 10 min and then % B (10–
100) for the remaining 40 min. Peptide absorbance in the
eluate was monitored at 214 nm.
Haemolytic activity assay
Normal RBCs were washed three times in sterile PBS.
After each wash, the tube was centrifuged at 450g for
5 min at 4C, and then PBS was added to reach a final
haematocrit concentration of 2%. Aqueous solutions of
peptides were prepared by 10 serial dilutions in sterile PBS
from a stock of 1 mM. Diluted peptides (0–300 lM,
150 lL) were added to suspend RBCs in each of 96 wells
in a microplate. The haemolytic assay was carried out in
triplicate, using 5% SDS as a positive control (100%
haemolysis). The plate was incubated with agitation at
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37C for 40 min, centrifuged at 400g during 5 min at 4C,
followed by aspiration of supernatant and finally measuring
the absorbance at 438 nm. Haemolysis of each concentra-
tion was calculated as a percentage by dividing the optical
density (OD) for each concentration by the OD for 5%
SDS.
Interactions between Cts and Plasmodium proteins
Plasmodium cultures were enriched with infected RBCs
(iRBCs) from 15% in the initial cultures to 80% following
Plasmagel treatment (Plasmion; Fresenius Kabi). Lysis of
iRBCs with 0.05% saponin was carried out as previously
described [42]. The solubilized Plasmodium was centri-
fuged for 5 min at 4,000g and washed three times in PBS.
The pellet was sonicated (4 9 10 s), centrifuged twice at
4,000g, and the second supernatant was kept for further
use. The two pellets were incubated with 0.05% Nonidet
P-40 (Sigma-Aldrich, St-Quentin, France) and sonicated.
The two resulting supernatants were pooled to constitute
the Plasmodium soluble extract (PSE). The protein content
was measured by Bradford assay (Bio-Rad, Marnes-
la-Coquette, France). PSE was separated on SDS-10%
PAGE under reducing conditions (in Bio-Rad apparatus).
After transfer to a PVDF membrane (Bio-Rad), the protein
bands were immunodetected using anti-MSP1 Mab (PEM-2;
Santa-Cruz Biotechnology, Heidelberg, Germany) and a
hyper-immune sera resulting from the pool of several
African residents infected by P. falciparum, and contain-
ing high levels of malaria antibodies measured by a
specific ELISA [43]. The secondary antibody was either
an anti-human IgG (Roche Diagnostics, Meylan, France)
or an anti-mouse IgG (Sigma, St Louis, MO, USA) con-
jugated to peroxydase, and the complex of antibodies and
protein was visualized by ECL-autoradiography (Pierce
ECL Western Blotting Substrate; Fisher Bioblock, Illkirch,
France). Specific interaction between PSE and Cts was
determined by incubating biotin-labelled peptides (100 lg
of Cts or scrambled Cts) with 100 lL of streptavidin-
conjugated Sepharose beads (GE Healthcare, Orsay,
France) under constant shaking for 2 h at 4C. The beads
were centrifuged at 15,000g for 15 min, and washed in
PBS containing a cocktail of proteases inhibitors (Roche
Diagnostics). The beads were incubated with 100 lg of
PSE under constant shaking overnight at 4C, then washed
four times in PBS and centrifuged at 15,000g for 15 min.
PSE proteins interacting with the biotinylated Cts were
identified by boiling the beads in 30 lL of Laemmli buffer
and separating on 10% SDS-PAGE, under reducing con-
ditions (Bio-Rad apparatus). Similar experiments were
conducted with biotinylated scrambled Cts as controls. 1D
SDS-PAGE gels were prepared for mass spectrometry
analysis.
In-gel digestion of separated components
Gels were systematically cut into slices and in-gel digestion
was performed with an automated protein digestion system,
MassPREP Station (Waters, Manchester, UK). The gel sli-
ces were washed three times in a mixture containing 25 mM
ammonium bicarbonate: acetonitrile (1:1, v/v). The cysteine
residues involved in disulfide bridges were reduced by
adding 50 lL of 10 mM dithiothreitol at 57C and alkylated
by adding 50 lL of 55 mM iodoacetamide. After dehy-
dration with acetonitrile, the proteins were cleaved with
40 lL of modified porcine trypsin (12.5 ng/lL; Promega,
Madison, WI, USA) in 25 mM ammonium bicarbonate, pH
7.2 at 37C for 4 h. Finally, the tryptic peptides were
extracted with 60% acetonitrile in 5% formic acid, followed
by a second extraction with 100% (v/v) acetonitrile.
Mass spectrometry analysis of tryptic digests
NanoLC-MS/MS analysis was performed on a nanoAC-
QUITY Ultra-Performance-LC (UPLC; Waters) coupled to
a hybrid quadrupole orthogonal acceleration time-of-flight
tandem mass spectrometer (SYNAPTTM MS; Waters). Each
sample was loaded on a 20 9 0.18 mm, 5 lm Symmetry
C18 precolumn (Waters), and the peptides were separated
on a ACQUITY UPLC BEH130 C18 column (Waters)
(200 9 0.075 mm, 1.7 lm particle size). The solvent sys-
tem consisted of 0.1% formic acid in water (solvent A) and
0.1% formic acid in acetonitrile (solvent B). Trapping was
performed for 3 min at 5 lL/min with 99% of solvent A and
1% of solvent B. Elution was performed at a flow rate of 400
nL/min, using 1–40% gradient (solvent B) over 35 min at
45C followed by 65% (solvent B) over 5 min.
The MS and MS/MS analyses were performed on the
SYNAPTTM (Waters) equipped with a Z-spray ion source
in positive mode. The capillary voltage was set at 3.5 kV
and the cone voltage at 35 V. The SYNAPT is equipped
with a lock-mass system. Mass calibration of the TOF in
the 50–2,000 m/z range was achieved using phosphoric
acid. In line correction of this calibration was achieved
using lock-mass on product ions derived from the [Glu1]-
fibrinopeptide B (GFP).
The ion (M ? 2H)2? at m/z 785.8426 is used to cali-
brate MS data and the fragment ion (M ? H)? at m/z
684.3469 is used to calibrate MS/MS data.
For tandem MS experiments, the system was operated
with automatic switching between MS and MS/MS
modes (MS 0.5 s/scan on m/z range 250–1,500 and MS/MS
0.7 s/scan on m/z range 50–2,000). The three most abundant
peptides (intensity threshold 60 counts/s), preferably doubly
and triply charged ions, were selected on each MS spectrum
for further isolation and CID fragmentation. Fragmentation
was performed using argon as the collision gas. To improve
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the quality of MS/MS spectra during NanoLC-MS/MS
analysis, we empirically derived energy curves depending
on the m/z value of the selected precursor ion. For each m/z
value, two different collision energies were applied.
The complete system was fully controlled by MassLynx
4.1 (SCN 566; Waters). Raw data collected during
NanoLC-MS/MS analyses were processed and converted
with ProteinLynx Browser 2.3 (23; Waters) into pkl peak
list format. Normal background subtraction type was used
for both MS and MS/MS with a 5% threshold and polyno-
mial correction of Order 5 and deisotoping was performed.
Protein identification
The MS and the MS/MS data were analyzed using a local
Mascot server (version MASCOT 2. 2. 0; MatrixScience,
UK) and a composite target-decoy database including the
protein sequences of the UniProtKB/Swiss-Prot version
55.2 and reversed versions of these sequences (total 719,
884 entries).
Searches were performed with a mass tolerance of
50 ppm for MS mode and 0.2 Da in MS/MS mode. One
missed cleavage per peptide was allowed and variable
modifications were taken into account such as carbami-
domethylation of cysteine and oxidation of methionine.
To minimize false positive identifications, the results
were subjected to stringent filtering criteria. For the iden-
tification of a protein with two peptides or more, at least
two unique peptides had to fit a Mascot ion score above 25.
In the case of single peptide hits, the score of the unique
peptide must be greater than 50. For estimation of the false
positive rate, a target-decoy database search was performed
[44, 45]. With this approach, peptides are matched against
a database consisting of the native protein sequences found
in the database (target) and of the sequence-reversed
entries (decoy). The evaluations were performed using the
peptide validation software Scaffold (Proteome Software,
Portland, USA). This strategy was used to obtain a final
catalogue of proteins with an estimated false positive rate
below 1%.
Plasmepsin kinetic assay
Wild-type recombinant plasmepsins proenzymes (PM II
and IV) were expressed and purified as previously descri-
bed [46, 47]. For the kinetic assays, the enzyme was
incubated in 0.1 M sodium acetate, pH 4.5 for 5 min at
37C to allow autoconversion to the mature enzyme and
interaction with the inhibitor. The enzyme (free or inhibi-
tor-complexed form) was mixed with a chromogenic
substrate [46] and the initial rates of cleavage were mea-
sured using a Cary 50 Bio UV–Visible spectrophotometer
for at least six defined substrate concentrations and at least
two different concentrations of inhibitors. Ki values were
determined using SigmaPlot (Systat Software) [48].
Statistical analysis
The efficacy of the different peptide concentrations relative
to the control was evaluated using the Kruskal–Wallis test.
Different substrate concentrations with different rates of
inhibition are presented in bar graphs and compared to the
control inhibition rate, considering that parasitemia in the
control bar will represent 0% inhibition. The test was
performed three times to assure reproducible results.
P values \ 0.05 for difference from controls were con-
sidered significant. Statistical analysis was done using
GraphPad Instat software (San Diego, CA, USA).
Results
Cts inhibits Plasmodium falciparum growth
Peptide activities against Plasmodium strains’ growth were
measured in vitro. Maximal growth inhibition of the 3D7
strain was reached with 20 lM hCts (Fig. 1a). When we
assayed hCts at the same concentration on two other strains,
7G8 (CQ resistant) and W2 (multidrug resistant), we
reached 64 and 62%, respectively (Fig. 1b). Similar results
were observed for ring-form stages and schizonts of the
same P. falciparum strain (data not shown). The chloro-
quine-resistant P. falciparum strain 7G8 strain was less
sensitive to hCts with growth inhibited by 36% at 20 nM
and 64% at 20 lM (Fig. 2a). Similarly, the growth of the
multidrug-resistant P. falciparum strain W2 was inhibited
by 22 and 62% at 20 nM and 20 lM, respectively (Fig. 2b).
The production of pLDH persisted in these non-prolif-
erating stage 48 h later, consistent with a viable state of the
growth-inhibited parasite in the presence of hCts (Fig. 2a).
We have estimated the half-life of hCts to 12 h by HPLC
and Edman sequencing (data not shown). Therefore, we
added successive amounts of peptide to cell cultures, but
the inhibitory performance was not improved, and we did
not observe any kind of haemolytic activity (data not
shown). The IC50 was estimated at 14 lM by pLDH
measurement (Fig. 2b), pointing out that complete growth
inhibition never exceeded 90% at any tested concentration
higher than 20 lM hCts.
Structure–activity relationship studies
of Cts against the 3D7 strain
Human Cts was more active than the bovine peptide with
respect to growth inhibitory effects on the 3D7 strain. The
sequence similarity between the two Cts peptides is 90%
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[13–19] (Fig. 3). Four substitutions are apparent in posi-
tions 1, 4, 11, and 19 of the 21 residues, resulting in a
higher cationic charge (?5) in bCts and bCTL than in hCts
(?4) (Fig. 3). Notably, the substitutions of the serine res-
idue in position 1 of hCts to arginine in bCts and bCTL,
and of the alanine residue in position 11 of hCts to glycine
in bCts and bCTL may be important for the higher inhib-
itory potency of hCts. In order to identify the region of Cts
crucial for the antiplasmodial activity, several truncated
peptides were also compared for growth inhibition of the
chloroquine-sensitive strain, 3D7 (Fig. 3). The N-terminal
region (Cat 1) and the median region (Cat 3) from which a
glycine residue in position 13 was deleted were found to be
as effective as the intact bCts. In contrast, the C-terminal
region (Cat 2) and the scrambled hCts were devoid of
inhibitory effects, while the shortest peptide (Cat 4),
comprising the highly conserved sequence LSFR, was able
to inhibit parasite growth by 50% (Fig. 3). Altogether,
these data demonstrate the importance of the LSFR
sequence for evaluating antiplasmodial activity.
Identification of plasmodial protein targets
by mass spectrometry analysis
Soluble extracts of Plasmodium cultures were incubated
with biotinylated hCts (or scrambled hCts as a negative
Fig. 1 In vitro action of human Cts (hCGA352–372) on the growth of
P. falciparum strains. a Parasitemia (%) was evaluated after adding
hCts (20 nM–50 lM) to cultured P. falciparum strain 3D7 during
4 days post-infection (D0–D4). Maximal growth inhibition of 3D7
strain was reached with 20 lM; Control corresponds to P. falciparum
3D7 strain culture with the inactive scrambled hCts (20 lM).
b Growth inhibition induced by 20 lM of hCts on P. falciparum
chloroquine sensible strain 3D7, chloroquine-resistant strain 7G8, and
multidrug-resistant strain W2. Control corresponds to P. falciparum
3D7 strain culture with the inactive scrambled peptide (20 lM).
Results are expressed as mean and SD from three independent
experiments and were compared to control, *P \ 0.01
Fig. 2 a Measurement by ELISA (A450 nm) of Plasmodium lactate
dehydrogenase antigen (pLDH), as a reflection of parasite growth.
P. falciparum 3D7 strain was cultured for 0 and 48 h without Cts and
with Cts (2.5–50 lM). b hCts IC50 was measured on P. falciparum 3D7
strain with the ICEstimator (http://www.antimalarial-icestimator.net/)
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control) and streptavidin-conjugated Sepharose beads
overnight at 4C. The parasite proteins bound to the
washed beads were eluted at 100C and identified by mass
spectrometry analysis of components separated by 1D SDS-
PAGE. The gels were systematically cut into 46 bands and
treated in-gel with trypsin. The tryptic released peptides
were analyzed by nano LC–MS/MS. Three parasite
proteins were specifically pulled down by Cts: tubulin beta
chain (P14643), proliferating cell nuclear antigen (P31008)
and a precursor of plasmepsin II (P46925) (Table 2,
and electronic supplementary data: mass spectrometry-
proteomic analysis).
Inhibition of Plasmepsin activities by Cts
An in vitro assay was established to assess the putative
inhibitory potencies of Cts on recombinant PfPM2 and
PfPM4 (PfPM: P. falciparum plasmepsin) (Table 3). Ki
values of 130–140 nM hCts were obtained for both PfPM2
and PfPM4. In contrast, the Ki values for the scrambled
hCts for both enzymes were 26 and 40 fold higher,
respectively, while the Ki values for the shortest active
peptide LSFR were 14- to 15-fold higher than for hCts.
Plasmepsin IV homologues are found in the remaining
species of Plasmodium known to infect man: P. ovale,
P. vivax, and P. malariae. When we compared the Ki
values for hCts for these plasmepsins to those obtained for
PfPM4 (Table 3), the order of inhibitory potency of hCts
was: PfPM4 [ PvPM4  PoPM4  PmPM4. For all four
Plasmodium species, the order of inhibitor potencies was
hCts [[ LSFR [ scrambled hCts.
Discussion
In the present study, we have shown for the first time that
hCts, the natural cationic antimicrobial CgA-derived pep-
tide, inhibits Plasmodium growth in vitro, not only of the
chemo-sensitive strain 3D7, but also of the two drug-
resistant strains, 7G8 and W2, of P. falciparum. Until
100 lM, CTL, the active domain, does not display lytic
effect on RBCs and other host cells (human neuroblastoma
SKNMC and cardiomyocytes H9C2) (Jenny Briolat, Thesis
of the University of Strasbourg, 2006). The parasite
remains viable as assessed by persistence of a basic pLDH
production in the presence of hCts, also suggesting a role
for this CgA peptide in the first line of defence against
invasion of this pathogen, and explaining why growth
inhibition was never complete. Recently, our group has
demonstrated the immunomodulatory properties of Cts by
stimulating neutrophils [49]. Although yet to be demon-
strated during human or rodent malaria infections, Cts
Fig. 3 In vitro inhibition (%) of the growth of P. falciparum strain
3D7 by several Cts-derived peptides at 20 lM: hCts, bCts, CTL
(bCGA344–358), Cat 1 (bCGA344–351), Cat 2 (hCGA360–372), Cat 3
(bCGA348–358 with deletion of G357), Cat 4 (bCGA348–351), and
scrambled hCts, Control corresponds to Plasmodium growth without
peptide. Each peptide was incubated in MCM at 20 lM concentration
for 48 h before analysis by pLDH-ELISA. Results are expressed
as mean and SD correspond to three independent experiments,
*p \ 0.01
Table 2 Putative targets of Cts identified by mass spectrometry
Protein name Accession numbers Protein molecular
weight (AMU)
Catestatin
(%)
Scrambled
Catestatin
Tubulin beta chain: Plasmodium falciparum
(isolate K1/Thailand)
P14643|TBB_PLAFK,Q7KQL5|TBB_PLAF7 49,732.8 99 0
Plasmepsin-2 precursor: Plasmodium falciparum P46925|PLM2_PLAFA 51,473.8 99 0
Proliferating cell nuclear antigen: Plasmodium
falciparum (isolate K1/Thailand)
P31008|PCNA_PLAFK,P61074|PCNA_PLAF7 30,570.3 98 0
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secretion from neuroendocrine cells and PMNs triggered
by invading microorganisms [2] may also contribute to the
first defence against the P. falciparum infection.
Antimicrobial peptides selectively targeting pathogens
often present a broad spectrum of action. Several naturally
occurring antimicrobial peptides have been tested as
potential anti-plasmodium agents, including scorpin, mag-
ainin 2, cecropin B, defensin, and dermaseptin S3 and S4
[50–53], as well as the synthetic peptides Vida 1-3, P2WN,
ILF, SM1, SB-37, Shiva-1 and 3, and LAH4 [54–59]. Hence,
a discussion of the structural requirements for the Cts mol-
ecule, a peptide naturally present in humans, on parasite
growth, and on the inhibitory potential of the peptide on
parasite specific enzymes are important in this context. It is
evident from the present experiments that the Cts domain
LSFR by itself expresses a growth inhibitory potency (50%
inhibition of the 3D7 strain; Fig. 3). Intriguingly, the
N-terminal serine residue unique to hCts appeared essential
for maximal inhibition (88%) relative to the significantly
lower inhibitory effects of bCts and bCTL (63–67%), both
containing arginine as a substitute for the N-terminal serine.
Moreover, the bovine peptides Cat 1 and Cat 3, both con-
taining the LSFR-sequence, were equipotent with bCts and
CTL, while the scrambled hCts and the C-terminal Cat 3
were completely inactive. These findings strongly suggest
that the observed growth inhibitory potency on P. falciparum
is specific for the primary sequence of hCts and dependent
on the conservation of the LSFR domain.
Among the synthetic peptides described up to now as
inhibitors of Plasmodium growth are inhibitors of plasm-
epsin family members. They were found after homology
modeling and molecular docking [32]. Previous computa-
tional inhibitor design against malaria plasmepsin II [32]
demonstrates that the natural haemoglobin peptide
RMFLSF [32–38] is a substrate of the aspartic protease,
which rapidly cleaves haemoglobin between F33 and L34.
Interestingly, Cts sequence and LSFR both include the short
LSF fragment. This observation suggests that Cts might
interact with plasmepsin II as a competitive substrate.
A non-specific binding of the tetrapeptide cannot be
excluded despite the fact that LSFR, but not the scrambled
peptide, partially arrested Plasmodium growth in vitro. The
mechanism underlying this phenomenon will be a topic for
future experiments. Indeed, the identification by mass
spectrometry of Cts binding proteins in Plasmodium extract
show the presence of tubulin beta chain, proliferating cell
nuclear antigen and plasmepsin II precursor. It cannot be
excluded that Cts might interact with parasite microtubules
[60, 61] or proliferating cell nuclear antigen [62] (Table 2),
but detection of plasmepsin II precursor attracted interest
because, as detailed above, parasite-specific aspartic pro-
teases of the plasmepsin family have a significant role in the
processing of haemoglobin. PfPM1, PfPM2, and PfPM4 are
localized in the digestive vacuole found in P. falciparum
[63–65], and the present data made it evident that hCts is
able to preferentially inhibit the in vitro activity of recom-
binant PfPM2 and PfPM4 of P. falciparum (Table 3). In
previous studies [47], the quadruple–PM KO 3D7 strain
showed a significantly slower rate of growth in standard
medium similar to the wild-type 3D7 treated with hCts
without lysis of parasites. Following these observations, we
can suppose that hCts can interact with plasmepsins and
inhibit their functions. The corresponding Ki values of
130–140 nM Cts suggest that these two PMs may be targets
for this peptide in this species of Plasmodium, in addition to
the sequence comparison with the natural substrate and the
incomplete Plasmodium growth inhibition. In addition, Cts
also showed good efficacy as a plasmepsin inhibitor on
resistant as well as sensitive P. falciparum strains (not
shown). Of interest, plasmepsin IV is shared by all four
Plasmodium species known to infect man. The present
experiments have shown that hCts is also able to inhibit,
albeit with significantly higher Ki values, the activity of
recombinant plasmepsin IV from P. ovale, P. vivax, and
P. malariae in vitro, demonstrating some inter-strain
inhibitory capacities (Table 3). Ki values for a series of
synthetic inhibitors of PfPM1 and PfPM2 are available in
the literature [66]. The Ki values for Cts on P. falciparum
were comparable, if not better, than those reported for most
synthetic inhibitors. Cts IC50 of the 3D7 strain (14 lM) is
high, when compared to chloroquine (IC50 = 18–38 nM).
However, Cts and its derived peptides may be interesting
for the exploration of new antimalarial drugs based upon
observed plasmepsin inhibition. Future experiments to
demonstrate that Cts is a new actor of innate immunity to
fight P. falciparum will involve detecting the presence
Table 3 Ki values in nM of catestatin, scrambled catestatin, and LSFR with plasmepsin II from P. falciparum, plasmepspin IV from all four
Plasmodium species known to infect man
Inhibitor/plasmepsin PfPM2 PfPM4 PoPM4 PvPM4 PmPM4
Ki (nM)
Catestatin 130 ± 10 140 ± 10 1,000 ± 120 320 ± 30 5,600 ± 770
Scrambled Catestatin 3,400 ± 310 5,600 ± 780 10,600 ± 1,300 2,800 ± 270 51,000 ± 6,000
LSFR 2,000 ± 200 1,900 ± 190 7,800 ± 850 1,400 ± 150 31,000 ± 2,400
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of Cts in human and in malaria-infected mice in acute
infection and determining its role in vivo.
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Appendix: List of Accession Numbers (Proteins)
hCgA (human Chromogranin A): P10645
bCgA (bovine Chromogranin A): P05059
mCgA (mouse Chromogranin A): P26339
rCgA (rat Chromogranin A): P10354
eCgA (equine Chromogranin A): Q9XS63
pCgA (pig Chromogranin A): P04404
fCgA (frog Chromogranin A): Q9W7A0_RANRI
pLDH (plasmodium Lactate DeHydrogenase): Q27743
PfTubulin b chain: P14643
Proliferating Cell Nuclear Antigen: P31008
PfPlasmepsin II precursor, PfPM2: P46925
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